Shafran Gastroenterology Center

Winterpark, Florida 70809

0 studies enrolling now · 41 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Inflammatory Bowel Disease, Known Crohn Disease Subjects, Proctitis, Ulcerative, Ulcerative Colitis

Studies at this site

• Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease — Completed
• Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease — Completed
• Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
• A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis — Completed
• Long-Term Safety Of PF-00547659 In Ulcerative Colitis — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis — Stopped early
• Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study — Completed
• A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease — Completed
• An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo — Completed
• Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects — Completed
• A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease — Completed
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis — Completed
• Does Clinical Response Correlate With Serum Certolizumab Levels? — Status unconfirmed
• A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease — Stopped early
• Dose Escalation and Remission (DEAR) — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis — Completed
• Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy — Completed
• Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis — Completed
• Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease — Completed
• Remission in Subjects With Crohn's Disease, 1 Year Phase — Completed
• Remission in Subjects With Crohn's Disease, Open Label Extension — Completed
• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease — Completed
• A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease — Completed